Stay updated on Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.

Latest updates to the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page
- Check3 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2 on the page.SummaryDifference0.1%

- Check11 days agoChange DetectedMinor revision update from v3.4.0 to v3.4.1 with no changes to study details or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe page shows a new revision label 'Revision: v3.3.4' replacing the previous 'Revision: v3.3.3'. This is a minor technical update with no impact on the study information.SummaryDifference0.1%

- Check54 days agoChange DetectedA consolidated Locations section listing Arizona, Florida, and Minnesota was added, while the prior Arizona/Florida/Minnesota location subsections were removed; the page revision was updated to v3.3.3.SummaryDifference0.4%

- Check83 days agoChange DetectedThe page displays a new revision label: v3.3.2 replacing the previous v3.2.0.SummaryDifference0.1%

- Check90 days agoChange DetectedThe government funding status notice banner has been removed from the page, removing administrative operating information unrelated to trial details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.